Jean-Baptiste Fassier

Jean-Baptiste Fassier

Auto-generated profile, based on publicly available information

Jean-Baptiste Fassier

Unité Mixte de Recherche Epidémiologique et de Surveillance Transport Travail Environnement (UMRESTTE), Hospices Civils de Lyon, Université Claude Bernard Lyon 18, Avenue Rockefeller, 69673, Lyon Cedex 08, France

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JLJonathan Lopez
Jonathan Lopez
MMMarine Mommert
Marine Mommert
WMWilliam Mouton
William Mouton
MPMario Andrés Pizzorno
Mario Andrés Pizzorno
KBKaren Brengel-Pesce
Karen Brengel-Pesce
STSophie Trouillet-Assant
Sophie Trouillet-Assant
IFN-I and IFN-III immunity in the nasal mucosa is poorly characterized during SARS-CoV-2 infection. We analyze the nasal IFN-I/III signature, namely the expression of ISGF-3–dependent IFN-stimulated genes, in mildly symptomatic COVID-19 patients and show its correlation with serum IFN-α2 levels, which peak at symptom onset and return to baseline from day 10 onward. Moreover, the nasal IFN-I/III signature correlates with the nasopharyngeal viral load and is associated with the presence of infectious viruses. By contrast, we observe low nasal IFN-I/III scores despite high nasal viral loads in a subset of critically ill COVID-19 patients, which correlates with the presence of autoantibodies (auto-Abs) against IFN-I in both blood and nasopharyngeal mucosa. In addition, functional assays in a reconstituted human airway epithelium model of SARS-CoV-2 infection confirm the role of such auto-Abs in abrogating the antiviral effects of IFN-I, but not those of IFN-III. Thus, IFN-I auto-Abs may compromise not only systemic but also local antiviral IFN-I immunity at the early stages of SARS-CoV-2 infection.

1 December 2021 in Joint Bone Spine
Verified
Journal Article
Closed access
FBFlorian Bailly
Florian Bailly
ATAnne-Priscille Trouvin
Anne-Priscille Trouvin
SBSandrine Bercier
Sandrine Bercier
SDSabrina Dadoun
Sabrina Dadoun
JDJean-Philippe Deneuville
Jean-Philippe Deneuville
PAPetit Audrey
Petit Audrey

4 October 2016 in Journal of Occupational Rehabilitation
Verified
Journal Article
Open access
PDF file
TPthe Hopkinton Conference Working Group on Workplace Disability Prevention
the Hopkinton Conference Working Group on Workplace Disability Prevention
GPGlenn S. Pransky
Glenn S. Pransky
JFJean-Baptise Fassier
Jean-Baptise Fassier
EBElyssa Besen
Elyssa Besen
PBPeter Blanck
Peter Blanck
FMFehmidah Munir
Fehmidah Munir
Introduction Many disability prevention strategies are focused on acute injuries and brief illness episodes, but there will be growing challenges for employers to manage circumstances of recurrent, chronic, or fluctuating symptoms in an aging workforce. The goal of this article is to summarize existing peer-review research in this area, compare this with employer discourse in the grey literature, and recommend future research priorities. Methods The authors participated in a year-long sponsored collaboration that ultimately led to an invited 3-day conference, “Improving Research of Employer Practices to Prevent Disability”, held October 14–16, 2015, in Hopkinton, Massachusetts, USA. The collaboration included a topical review of the scientific and industry literature, group discussion to identify key areas and challenges, drafting of initial documents, and feedback from peer researchers and a special panel of experts with employer experience. Results Cancer and mental illness were chosen as examples of chronic or recurring conditions that might challenge conventional workplace return-to-work practices. Workplace problems identified in the literature included fatigue, emotional exhaustion, poor supervisor and co-worker support, stigma, discrimination, and difficulties finding appropriate accommodations. Workplace intervention research is generally lacking, but there is preliminary support for improving workplace self-management strategies, collaborative problem-solving, and providing checklists and other tools for job accommodation, ideas echoed in the literature directed toward employers. Research might be improved by following workers from an earlier stage of developing workplace concerns. Conclusions Future research of work disability should focus on earlier identification of at-risk workers with chronic conditions, the use of more innovative and flexible accommodation strategies matched to specific functional losses, stronger integration of the workplace into on-going rehabilitation efforts, and a better understanding of stigma and other social factors at work.

15 March 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
VBVéronique Barateau
Véronique Barateau
LPLoïc Peyrot
Loïc Peyrot
CSCarla Saade
Carla Saade
BPBruno Pozzetto
Bruno Pozzetto
KBKaren Brengel-Pesce
Karen Brengel-Pesce
TDThierry Defrance
Thierry Defrance
The diversity of vaccination modalities and infection history are both variables that have an impact on the immune memory of individuals vaccinated against SARS-CoV-2. To gain more accurate knowledge of how these parameters imprint on immune memory, we conducted a long-term follow-up of SARS-CoV-2 spike protein–specific immune memory in unvaccinated and vaccinated COVID-19 convalescent individuals as well as in infection-naïve vaccinated individuals. Here, we report that individuals from the convalescent vaccinated (hybrid immunity) group have the highest concentrations of spike protein–specific antibodies at 6 months after vaccination. As compared with infection-naïve vaccinated individuals, they also display increased frequencies of an atypical mucosa-targeted memory B cell subset. These individuals also exhibited enhanced T H 1 polarization of their SARS-CoV-2 spike protein–specific follicular T helper cell pool. Together, our data suggest that prior SARS-CoV-2 infection increases the titers of SARS-CoV-2 spike protein–specific antibody responses elicited by subsequent vaccination and induces modifications in the composition of the spike protein–specific memory B cell pool that are compatible with enhanced functional protection at mucosal sites.

25 August 2016 in Journal of Occupational Rehabilitation
Verified
Journal Article
Closed access
PDF file
MCMarc Corbière
Marc Corbière
ANAlessia Negrini
Alessia Negrini
MDMarie-José Durand
Marie-José Durand
LSLouise St-Arnaud
Louise St-Arnaud
CBCatherine Briand
Catherine Briand
JLJean-Philippe Lachance
Jean-Philippe Lachance

16 December 2017 in Psycho-Oncology
Verified
Journal Article
Closed access
PDF file
MLMarion Lamort‐Bouché
Marion Lamort‐Bouché
PSPhilippe Sarnin
Philippe Sarnin
GKGerjo Kok
Gerjo Kok
SRSabrina Rouat
Sabrina Rouat
JPJulien Péron
Julien Péron
JFJean‐Baptiste Fassier
Jean‐Baptiste Fassier